A new publication in Diabetes Research and Clinical Practice explores the perceived and demonstrated benefits of continuous glucose monitors (CGM) use for people at risk of developing Type 2 diabetes (T2D), including those living with obesity or intermediate hyperglycaemia, and for those diagnosed with T2D. The article, titled “The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes”, was supported and facilitated by IDF Europe.
About the publication
Obesity, intermediate hyperglycaemia (often referred to as prediabetes) and T2D represent a significant and growing burden for individuals, economies and societies. In Europe, T2D accounts for more than 90% of the 66 million people living with diabetes and the number is expected to rise further. Obesity is a significant risk factor for the development of both intermediate hyperglycaemia and T2D. It is also estimated that more than one-third of people living with diabetes remain undiagnosed. When undiagnosed, diagnosed late or not optimally managed, T2D can lead to various life-altering complications such as cardiovascular disease, kidney disease and eye disease. Much of the burden associated with diabetes is also placed on health systems, with about 75% of diabetes costs related to treating these often-preventable complications.
The use of CGM technology in people at risk of intermediate hyperglycaemia or T2D can significantly improve the rate and timing of diagnosis. Early detection allows for early intervention that can help delay or even prevent harmful progression of the condition. CGMs also play a role not just at the detection stage but also in helping people manage T2D, as they support understanding of the condition and how to recognise and manage daily glucose fluctuations in relation to their lifestyle and/or medical therapy.
Although further research is needed to fully understand the cost-effectiveness of using this technology among people living with these conditions, the proposition for the use of CGMs is clear and holds much potential to reduce disease burden and make prevention and care strategies more effective. However, inequalities in access to self-management technologies exist between countries and other barriers such as low digital and health literacy still pose obstacles to their utilisation. Addressing these gaps will also be key to their meaningful uptake.
